Drug Approval | January 02, 2025
Innovent receives NMPA approval for Taletrectinib Adipate capsule from NMPA
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Subscribe To Our Newsletter & Stay Updated
